Shield managing director (MD) to retire
This article was originally published in Clinica
Shield Diagnostics managing director Gordon Hall has announced his retirement, to take place immediately. This comes at an awkward time for the UK company, which is in negotiations for a licensing agreement for its AFT heart attack prediction test. Shares in the company fell 100p to 617.5p on the news.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.